We offer many prenatal evaluations, fetal monitoring and screening tools that are designed to answer your questions, and detect or rule out potential issues with your baby’s development. Any information learned during pregnancy about fetal abnormalities is used to develop an individualized treatment and delivery plan before birth.
Common screenings and diagnostic procedures include:
This screening at 15 weeks involves extracting a small sample of amniotic fluid to identify or rule out chromosome abnormalities such as Down syndrome, birth defects such as spina bifida, or genetic conditions, such as cystic fibrosis.
Cervical Length Assessment:
This examination uses transvaginal ultrasound to verify an incidental finding of a potentially short cervix that could lead to preterm delivery.
Cell-Free Fetal DNA Screening:
This mother’s blood test, performed as early as 11 weeks, is used to learn more about baby’s Rh blood factor type or potential for chromosomal abnormalities, such as Down syndrome. Ohio State was one of the testing sites for this new screening process.
Chorionic Villus Sampling (CVS):
This diagnostic test at 10-12 weeks takes a sample of the developing placenta for laboratory analysis to identify or rule out chromosome abnormalities, such as Down syndrome and certain genetic disorders, such as cystic fibrosis.
This specialized ultrasound screening measures blood flow through a variety of blood vessels including the umbilical cord and brain.
Fetal Blood Sampling (Cordocentensis):
This blood test takes a small amount of baby’s blood from the umbilical cord for laboratory analysis to help in diagnosing and monitoring a variety of conditions.
This special ultrasound evaluates the structure and function of baby’s heart before birth to detect congenital heart defect.
Microarray Analysis Screening:
Using a blood sample, this chromosome screen (usually ordered because of a potential genetic condition in the family) determines if there is an extra or missing gene that may affect baby’s growth or development.
This state-of-the-art imaging technique evaluates baby’s size, position and development in diagnosing developmental abnormalities.
Ultrascreen Instant Risk Assessment/First Trimester Screening:
This early-pregnancy assessment at 11-13 weeks combines blood tests with ultrasound to deliver a personalized risk assessment for Down syndrome, trisomy 18 and trisomy 13. Ohio State’s Maternal Fetal Medicine Division was the first in central Ohio to offer this faster, more accurate, non-invasive procedure.
>This blood test administered at 15-22 weeks screens for open neural tube defects (NTDs), such as spina bifida and anencephaly, abdominal wall defects, and chromosome changes, such as Down syndrome and trisomy 18.